West Pharmaceutical Services Inc. (WST) Shares Sold by Legal & General Group Plc

Legal & General Group Plc reduced its holdings in West Pharmaceutical Services Inc. (NYSE:WST) by 3.8% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 88,792 shares of the medical instruments supplier’s stock after selling 3,534 shares during the quarter. Legal & General Group Plc owned about 0.12% of West Pharmaceutical Services worth $8,816,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Burt Wealth Advisors increased its holdings in shares of West Pharmaceutical Services by 113.7% during the second quarter. Burt Wealth Advisors now owns 4,128 shares of the medical instruments supplier’s stock valued at $410,000 after acquiring an additional 2,196 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of West Pharmaceutical Services by 6.3% during the first quarter. Schwab Charles Investment Management Inc. now owns 321,933 shares of the medical instruments supplier’s stock valued at $28,424,000 after acquiring an additional 18,960 shares in the last quarter. Sei Investments Co. increased its holdings in shares of West Pharmaceutical Services by 56.0% during the second quarter. Sei Investments Co. now owns 85,778 shares of the medical instruments supplier’s stock valued at $8,517,000 after acquiring an additional 30,795 shares in the last quarter. Aperio Group LLC increased its holdings in shares of West Pharmaceutical Services by 2.2% during the first quarter. Aperio Group LLC now owns 44,989 shares of the medical instruments supplier’s stock valued at $3,972,000 after acquiring an additional 978 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in shares of West Pharmaceutical Services by 13.9% during the first quarter. PNC Financial Services Group Inc. now owns 21,892 shares of the medical instruments supplier’s stock valued at $1,933,000 after acquiring an additional 2,672 shares in the last quarter. Institutional investors and hedge funds own 95.99% of the company’s stock.

In related news, SVP Karen Flynn sold 20,458 shares of the company’s stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of $116.23, for a total transaction of $2,377,833.34. Following the completion of the sale, the senior vice president now owns 31,051 shares in the company, valued at $3,609,057.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.90% of the company’s stock.

Several equities research analysts have recently commented on the company. Zacks Investment Research downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Friday, August 10th. ValuEngine upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a report on Tuesday, June 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $107.00.

NYSE WST opened at $120.58 on Friday. The company has a market cap of $8.66 billion, a PE ratio of 43.37, a PEG ratio of 4.00 and a beta of 1.20. West Pharmaceutical Services Inc. has a 52 week low of $82.74 and a 52 week high of $121.14. The company has a quick ratio of 1.94, a current ratio of 2.67 and a debt-to-equity ratio of 0.15.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.03. West Pharmaceutical Services had a return on equity of 15.38% and a net margin of 8.99%. The business had revenue of $447.50 million during the quarter, compared to the consensus estimate of $422.57 million. During the same quarter in the prior year, the company posted $0.66 earnings per share. West Pharmaceutical Services’s revenue was up 12.6% compared to the same quarter last year. equities analysts anticipate that West Pharmaceutical Services Inc. will post 2.82 earnings per share for the current fiscal year.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Read More: Diversification

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply